Clinical Trial

Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long COVID. All patients will also be provided with with Dietary \& Lifestyle recommendations specifically designed to enhance immune system function and reduce viral proliferation. Patients will be assessed in the clinic at screening/baseline, 3 and 6 weeks while on treatment, and by telephone at 4 weeks post-treatment. All patients will be asked to fill in a diary to record their daily treatment dosage when being treated with PNMR + SOC or with SOC alone. Primary objective: To evaluate the efficacy of PNMR + (SOC) vs. SOC in the treatment and management of patients with long COVID.
Trial Details
NCT Number NCT07627815
Lead Sponsor ParagonClinicals Inc.
Conditions Long COVID
Enrollment 82 participants
Start Date 2026-05-20
Primary Completion 2026-08-26 (estimated)
Study Completion 2026-12-26 (estimated)
Updated on ClinicalTrials.gov 2026-06-04